Researchers have successfully created lab-grown mini-intestines that accurately predict how drugs are processed by the human body, matching real-world drug behavior with high precision. According to Gram Research analysis, these three-dimensional enteroids developed the same protein profiles and functional characteristics as actual human intestinal tissue and correctly predicted the metabolism of two test drugs (terfenadine and midazolam). This breakthrough could reduce reliance on animal testing and improve drug safety assessment before human trials begin.

Scientists created tiny, three-dimensional copies of human intestines in the lab that behave like real intestines. These mini-guts, called enteroids, can absorb nutrients, filter harmful substances, and process drugs the same way your actual intestines do. According to Gram Research analysis, this breakthrough means pharmaceutical companies could test new medications on human tissue grown in dishes instead of using animals or less accurate cell cultures. The research shows these lab-grown intestines accurately predict how drugs move through your body, which could speed up drug development and make medicines safer before they reach patients.

Key Statistics

A 2026 research study published in iScience demonstrated that lab-grown three-dimensional jejunal enteroids accurately predicted first-pass drug metabolism and clinical pharmacokinetics for terfenadine and midazolam, matching real-world human intestinal drug processing.

Researchers found that optimally differentiated suspension-grown enteroids exhibited mature epithelial morphology, intact barrier function, and clinically relevant transporter activity including P-glycoprotein and BCRP expression, closely resembling freshly isolated human intestinal tissue.

The study showed that lab-grown mini-guts progressively adopted protein profiles matching those of native villus enterocytes and human jejunal tissue, indicating successful maturation of the three-dimensional intestinal model.

The Quick Take

  • What they studied: Whether lab-grown mini-intestines can accurately mimic how real human intestines absorb drugs and nutrients
  • Who participated: The research used human tissue samples to grow enteroids (mini-guts) in laboratory conditions. No human subjects were directly involved in testing.
  • Key finding: The lab-grown intestines successfully predicted how two common drugs (terfenadine and midazolam) are processed by the body, matching real-world drug behavior with high accuracy
  • What it means for you: This technology could lead to faster, safer drug development and fewer animal tests. However, these lab-grown intestines are still a research tool and won’t replace human clinical trials for determining drug safety and effectiveness in real patients.

The Research Details

Researchers grew three-dimensional intestinal tissue from human cells in suspension (floating in liquid) rather than attached to a surface. They created two types of mini-guts: one with the normal structure (basal-out) and one with an inverted structure (apical-out) to test different configurations. Using advanced microscopy and protein analysis, they compared how these lab-grown intestines looked and functioned compared to freshly removed human intestinal tissue.

The team then tested whether these mini-guts could accurately process drugs the way real intestines do. They added two medications (terfenadine and midazolam) that are known to be broken down by intestinal enzymes and measured how the mini-guts handled them. They compared these results to what happens in actual human bodies using computer models that predict drug movement through the body.

This approach allowed researchers to test whether lab-grown tissue could replace animal models and traditional cell cultures for predicting how drugs behave in humans.

Current drug testing relies on animal models (like mice or rats) or flat, two-dimensional cell cultures that don’t accurately represent how human intestines really work. Three-dimensional mini-guts are much closer to real intestinal tissue because they have the proper structure, multiple cell types, and the same barrier function as actual intestines. This means predictions about drug behavior should be more accurate, potentially reducing the need for animal testing and improving drug safety before human trials begin.

This research was published in iScience, a peer-reviewed scientific journal. The study used multiple advanced techniques (quantitative proteomics, microscopy, metabolic testing) to validate their findings from multiple angles. The researchers compared their lab-grown tissue directly to freshly isolated human intestinal tissue, which is the gold standard for validation. However, the study did not specify the exact number of tissue samples or enteroid batches tested, which limits our ability to assess the consistency of results.

What the Results Show

The lab-grown mini-guts successfully developed the same protein profiles as real human intestinal tissue over time. This means the cells in the lab-grown intestines were producing the same proteins and structures as cells in actual intestines, indicating they were maturing properly.

When researchers tested the mini-guts’ ability to process drugs, the results were remarkably accurate. The lab-grown intestines correctly predicted how the body breaks down and absorbs terfenadine and midazolam, matching real-world drug behavior. This was confirmed using physiologically based pharmacokinetic modeling, which is a computer method that predicts how drugs move through the body.

The mini-guts also demonstrated intact barrier function, meaning they could properly filter substances and prevent unwanted materials from passing through, just like real intestines do. They showed active nutrient absorption and expressed important drug-transporting proteins (P-glycoprotein and BCRP), which are the cellular pumps that move drugs across the intestinal wall.

The research compared two different structural configurations of enteroids (basal-out and apical-out). Both types successfully matured and developed functional characteristics, though the apical-out configuration showed morphogenic (shape-related) advantages. The suspension culture method (growing the mini-guts floating in liquid rather than attached to a surface) proved superior to traditional attachment methods, allowing better development of three-dimensional structure.

Previous research has used flat cell cultures or animal models to predict drug behavior, but both have significant limitations. Flat cell cultures lack the three-dimensional structure and multiple cell types of real intestines, making them poor predictors of drug absorption. Animal models, while three-dimensional, have intestinal biology that differs from humans in important ways. This research demonstrates that lab-grown human enteroids bridge that gap, offering human-relevant results without the ethical concerns of animal testing.

The study did not specify the exact number of enteroid batches or tissue samples tested, making it difficult to assess how consistent these results are across different preparations. The research tested only two drugs, so it’s unclear whether the accuracy extends to all medications. The study was conducted in laboratory conditions, which may not perfectly replicate the complex environment inside a living human body, including factors like gut bacteria, immune system activity, and blood flow. Additionally, these mini-guts represent only the small intestine (jejunum) and don’t account for how drugs are processed in other parts of the digestive system.

The Bottom Line

High confidence: Lab-grown mini-guts show promise as a tool for pharmaceutical companies to test drug absorption and metabolism before human trials. Medium confidence: This technology may reduce the need for animal testing in drug development. Low confidence: These mini-guts will completely replace human clinical trials or animal models in the near term. Researchers should continue validating this approach with additional drugs and comparing results to human data.

Pharmaceutical companies developing new drugs should pay attention to this research as a potential tool for faster, more accurate drug testing. Patients may eventually benefit from safer drugs developed using this technology. Animal welfare advocates should find this encouraging as a step toward reducing animal testing. Regulatory agencies (like the FDA) may eventually use this data to inform drug approval decisions. People should not expect this to immediately change how drugs are tested or approved, as validation with more drugs and regulatory acceptance will take time.

This technology is still in the research phase. It will likely take 3 to 5 years for pharmaceutical companies to adopt and validate this approach for routine drug testing. Regulatory acceptance and integration into standard drug development processes could take 5 to 10 years. Patients are unlikely to see direct benefits from this research for at least 5 to 10 years, as new drugs developed with this technology must still go through traditional clinical trials.

Frequently Asked Questions

Can lab-grown mini-guts replace animal testing for drugs?

Lab-grown mini-guts show strong promise for predicting drug absorption and metabolism, potentially reducing animal testing. However, they cannot yet completely replace animal models or human clinical trials, as they represent only one part of the intestine and don’t account for whole-body effects.

How accurate are these lab-grown intestines at predicting how drugs work in real people?

A 2026 study found that lab-grown enteroids accurately predicted the metabolism of two test drugs, matching real-world human drug processing. However, testing has been limited to a small number of medications, so accuracy across all drug types remains to be determined.

When will pharmaceutical companies start using this technology to test new drugs?

This technology is still in the research validation phase. Pharmaceutical adoption will likely take 3 to 5 years, with regulatory acceptance potentially requiring 5 to 10 years. Full integration into standard drug development processes will take longer.

What makes these lab-grown mini-guts better than flat cell cultures for drug testing?

Lab-grown mini-guts have three-dimensional structure, multiple cell types, and intact barrier function like real intestines, whereas flat cell cultures lack this complexity. This makes mini-guts much better at predicting how drugs are actually absorbed and processed in the human body.

Are there any limitations to using these mini-guts for drug testing?

Yes. These mini-guts represent only the small intestine and don’t account for gut bacteria, immune system activity, or blood flow. Testing has been limited to two drugs, and the laboratory environment may not perfectly replicate conditions inside a living body.

Want to Apply This Research?

  • Users interested in drug safety and development could track their awareness of personalized medicine advances by logging when they learn about new drug testing technologies and noting which medications they take. This creates a personal record of how emerging science may affect their healthcare.
  • Users could set reminders to research the clinical trial status of medications they take or are considering, helping them stay informed about how new drugs are being tested and validated before reaching the market.
  • Long-term tracking could involve monitoring pharmaceutical news and regulatory announcements about new drug approvals, noting which ones may have used advanced testing methods like lab-grown intestinal tissue. Users could also track their own medication responses and share this data with healthcare providers to contribute to real-world drug effectiveness data.

This research describes a laboratory tool for studying drug metabolism and intestinal function. These lab-grown mini-guts are not intended for human use and are not a substitute for clinical trials or medical advice. If you are taking medications or considering new treatments, consult with your healthcare provider. This technology is still in the research phase and has not yet been integrated into standard drug approval processes. The findings represent promising preliminary research but require further validation before widespread pharmaceutical adoption.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Proteomic and functional profiling of suspended jejunal enteroids reveals pharmacokinetic fidelity to native intestine. , iScience (2026). PubMed 42866664 | DOI
Topics
lab-grown intestines drug testing alternatives enteroids pharmaceutical development animal testing replacement drug metabolism intestinal tissue engineering personalized medicine